E

Euclises Pharmaceuticals, Inc.

6 employees

Euclises Pharmaceuticals develops novel COX-2 inhibitors for the effective treatment of cancers in the lungs, colon, and pancreas.

Basic info

Industry

pharmaceutical manufacturing

Sectors

Biotechnology
Health Care
Pharmaceutical

Date founded

2011

Funding rounds raised

Total raised

$2M

from 17 investors over 17 rounds

E

Euclises Pharmaceuticals, Inc. raised $1.2M on December 1, 2016

Investors: St. Louis Arch Angels, Argonautic Ventures, iSelect Fund and Cultivation Capital

E

Euclises Pharmaceuticals, Inc. raised $22K on May 18, 2016

Investors: Cultivation Capital

E

Euclises Pharmaceuticals, Inc. raised $2M on September 23, 2015

Investors: St. Louis Arch Angels, iSelect Fund, ABC Laboratories, Missouri Technology Corporation and Cultivation Capital

E

Euclises Pharmaceuticals, Inc. raised $700K on April 7, 2015

Investors: St. Louis Arch Angels and Cultivation Capital

E

Euclises Pharmaceuticals, Inc. raised $1.3M on September 9, 2014

Investors: Helix Funds, ABC Laboratories and Missouri Technology Corporation

E

Euclises Pharmaceuticals, Inc. raised $18K on June 12, 2013

Investors: St. Louis Arch Angels

E

Euclises Pharmaceuticals, Inc. raised $175K on May 1, 2012

Investors: St. Louis Arch Angels

FAQ